Low-Dose Topiramate in Alcohol Dependence: A Single-Blind, Placebo-Controlled Study by Martinotti, G. et al.
Journal of Clinical Psychopharmacology
 




Full Title: Low-dose topiramate in alcohol dependence: a single-blind, placebo- controlled study
Article Type: Original Contribution
Keywords: topiramate, alcohol dependence, craving, anticonvulsants
Corresponding Author: Giovanni Martinotti, Ph.D.




Corresponding Author's Institution: Catholic University of Roma, Institute of Psychiatry
Corresponding Author's Secondary
Institution:
First Author: Giovanni Martinotti, Ph.D.
First Author Secondary Information:












Order of Authors Secondary Information:
Manuscript Region of Origin: ITALY
Abstract: Introduction: Topiramate and anticonvulsants in general are considered safe and
effective drugs for the treatment of alcohol dependence, even though topiramate-
induced adverse events are quite common, especially for high initial doses or if titration
to 300 mg/day is too rapid. The aim of the present study was to assess the efficacy and
tolerability profile of low-dose topiramate for relapse prevention.
Methods: Following detoxification, 52 patients were randomised into two groups: 26
patients received 100 mg of topiramate (per os, bid, daily), titrated over two weeks, and
26 patients received placebo. Both groups underwent rehabilitation, twice a week.
Results: After 6 weeks of treatment, compared to the placebo group, patients receiving
topiramate showed: 1) fewer drinking days (p<0.05); 2) less daily alcohol consumption
(p<0.05); 3) more days of treatment (p<0.05); 4) reduced levels of craving (OCDS) and
withdrawal symptoms (CIWA-Ar); 5)  improvement of anxiety, depression and
obsessive-compulsive symptom severity (SCL-90-R).
Conclusion: Despite the small sample size and the short follow-up period, the present
placebo-controlled study demonstrated the potential usefulness of topiramate, even
when administered at a dose of 100 mg/day, for the treatment of detoxified alcohol-
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dependent subjects, confirming results from previous  studies testing higher doses of
topiramate.
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Introduction: Topiramate and anticonvulsants in general are considered safe and effective 
drugs for the treatment of alcohol dependence, even though topiramate-induced adverse 
events are quite common, especially for high initial doses or if titration to 300 mg/day is 
too rapid. The aim of the present study was to assess the efficacy and tolerability profile of 
low-dose topiramate for relapse prevention. 
Methods: Following detoxification, 52 patients were randomised into two groups: 26 
patients received 100 mg of topiramate (per os, bid, daily), titrated over two weeks, and 26 
patients received placebo. Both groups underwent rehabilitation, twice a week. 
Results: After 6 weeks of treatment, compared to the placebo group, patients receiving 
topiramate showed: 1) fewer drinking days (p<0.05); 2) less daily alcohol consumption 
(p<0.05); 3) more days of treatment (p<0.05); 4) reduced levels of craving (OCDS) and 
withdrawal symptoms (CIWA-Ar); 5) improvement of anxiety, depression and obsessive-
compulsive symptom severity (SCL-90-R). 
Conclusion: Despite the small sample size and the short follow-up period, the present 
placebo-controlled study demonstrated the potential usefulness of topiramate, even when 
administered at a dose of 100 mg/day, for the treatment of detoxified alcohol-dependent 
subjects, confirming results from previous studies testing higher doses of topiramate. 
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Alcoholism and alcohol abuse are a worldwide public health concern causing 
significant morbidity and mortality
1
. Disulfiram, naltrexone and acamprosate have been 
approved for the treatment of alcohol dependence. However, their efficacy is limited and a 
significant number of subjects is treatment-resistant
2
. Furthermore, no single drug has been 
found to be effective in every case, and this is possibly linked to the multifactorial nature of 
the aetiology of alcoholism. Nalmefene has been recently approved in Europe for the 
treatment of alcohol dependence, but its long term effects on relapse prevention need to be 
further confirmed. 
Several anticonvulsants have been shown to be effective for the prevention of 
alcohol relapse
3,4,5,6,7
. Although the FDA has not approved these drugs for the treatment of 
alcohol use disorders yet, there is growing evidence in literature supporting their use. Some, 
i.e. topiramate, are currently deemed to be promising anti-craving substances
8,9
. 
Alcohol dependence treatment comprises two phases: the withdrawal phase and the 
relapse prevention phase. During the latter, management of craving is crucial. The use of 
topiramate and anticonvulsants in general is safe and effective in both phases. The efficacy 
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of anticonvulsants in preventing epileptic seizures during alcohol withdrawal is, in fact, 
well-established; furthermore, they are considered to interact with the reward system
8
. 
Moreover, the efficacy of some anticonvulsants in treating psychiatric symptoms in 
substance use disorder patients
10,11,12
 is also relevant, given the high number of alcohol-
dependent subjects presenting a dual diagnosis
13
. 
Topiramate, a sulfamate-substituted analogous of fructose-1,6-diphosphate, is a 
potent anti-epileptic
14
 with strong neuroprotective properties
15,16
. In treating alcohol 
dependence Johnson et al. proposed a neuropharmacological model by which topiramate 
decreases alcohol reinforcement and the propensity to drink
17,18
. These data have been 
confirmed by different studies in different settings
19,20,21
. According to this hypothesis, 
topiramate would be expected to suppress both acute and chronic alcohol consumption. 
This dual action of topiramate is thought to comprise an initial decrease in dopamine in the 
nucleus accumbens (NAcc) in response to alcohol use, leading to a subsequent reduction of 
its rewarding/reinforcing potential. This mechanism is exerted by the facilitation of the 
GABAA-mediated inhibitory impulses, which is a peculiar action of topiramate. In chronic 
alcoholism, characterized by VTA-DA hypofunction, one must drink more heavily in order 
to stabilize the system and obtain good levels of reinforcement. On the other hand, if a 
chronic drinker were to discontinue alcohol consumption abruptly, the consequent 
“rebound” in dopaminergic neuronal activity could trigger drinking. Topiramate is thought 
to restore VTA-GABA neuronal activity, and, consequently, normalize VTA-DA 
hypofunction. 
Topiramate has a linear profile across a wide range of doses, with a bioavailability 
of at least 80%. In addition, its interaction with other psychotropic drugs is scarce, though it 
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may worsen sedation and central nervous system depression, if taken with barbiturates, 
benzodiazepines, opiates and alcohol itself
9
. 
The adverse event profile of topiramate is favourable; symptoms are generally 
either mild or moderate. Common adverse events include: paraesthesia, anorexia, taste 
perversion, lack of concentration, memory impairment (including world-naming), 
psychomotor disturbance, and general cognitive impairment, which can be observed in 10% 
of individuals taking topiramate
22
. The occurrence of topiramate-induced adverse events 
increases if high initial doses are given or if titration to 300 mg/day is too rapid
9
. Cognitive 
impairment is particularly relevant for alcohol-dependent patients, who generally present 
with reduced cognitive performance
23,24
. The use of low doses of topiramate is, therefore, 
particularly promising in these patients, as reported in an open-label study in which add-on 
topiramate reduced craving in alcohol-dependent detoxified subjects
25
. 
The aim of the present study was to assess the efficacy and tolerability profile of 
low-dose topiramate for relapse prevention. Primary outcome measures included: 
abstinence by the end of the study period, number of alcohol drinking days, daily alcohol 
consumption. Craving reduction, improvement of psychiatric symptoms, and assessment of 







Sixty-four subjects (M/F 4/1; mean age 46.36 ± 11.8; mean daily drinks 8.5 ± 3.5; 
mean years of addiction 16.8 ± 6.7) with a history of alcohol use disorders lasting at least 
three years, daily alcohol intake of at least 6 units (1 drink= 12 grams of absolute alcohol), 
and currently meeting clinical criteria for Alcohol Dependence (DSM-IV-TR), were 
consecutively recruited at the Day-Hospital (outpatient unit) of Psychiatry and Drug 
Dependence of the University General Hospital “A. Gemelli” in Rome (n= 25) and among 
outpatients referring to the Alcohol use disorders unit of “Villa Silvia” at Senigallia (AN) 
(n=27). Patient enrolment started in August 2009 and was completed in August 2012. We 
included only patients who declared their commitment to the goal of total abstinence. 
Patients were assessed by attending psychiatrists using the Structured Clinical Interview for 
DSM-IV (SCID I; SCID II). Patients were excluded if they had a severe physical illness or 
evidence of severe mental disorders interfering with their cognitive abilities. Other 
exclusion criteria were: regular use of anticonvulsants, antidepressants or antipsychotics; 
pregnancy or lactation; a history of severe adverse reactions or well-known hypersensitivity 
to topiramate or benzodiazepines; previous treatment with topiramate. 
The study was approved by the Institutional Review Board and national regulatory 
authorities in accordance with local requirements, and was conducted in accordance with 
Good Clinical Practice guidelines and the Declaration of Helsinki (1964) and subsequent 
revisions. After receiving information on the drug (possible side effects and dosing rate), all 
patients (or their legal representatives) provided written informed consent prior to 
randomisation. Patients were free to leave the study at any time. 
 
 6 
Procedures and assessments 
 
 
All subjects underwent detoxification with diazepam for a period of 5 to 10 days, according 
to a validated protocol
6,12
. Twelve patients did not complete detoxification, and they were 
excluded from the study before randomisation procedures. 
Following detoxification, 52 patients were randomised into two groups: 26 patients 
received 25 mg (per os, daily) of topiramate (TOP) during the first week, followed by 50 
mg (per os, bid, daily) for the second week, and 100 mg (per os, bid, daily) for the 
remainder of the clinical trial; 26 patients received an initial dose of 1 tablet of placebo 
(PLA) then increased to 2 tablets (per os, bid, daily) over one week. 
Randomization was performed using a common computer-generated system. Study 
personnel were unaware of the randomization sequence. 
A flow diagram showing patient distribution according to treatment group is 
presented in figure 1. At the beginning of each week of treatment, the drug was supplied to 
both the patient and a selected family member. A schedule was also provided to control for 
compliance. Tablets were identical in appearance, and they were tested during the trial to 
confirm stability. 
Throughout the entire study period, patients joined a supportive self-help group held 
by counsellors and psychologists twice a week. Random assignment was stratified 
according to the presence of a comorbid psychiatric diagnosis to ensure a relative balance 
in the overall prevalence of dual diagnosis among groups. 
Subjects were assessed at the beginning (T0) and at the end of treatment (6 weeks, 
T1). The drug was gradually discontinued over a period of seven days after the last 
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assessment. The study was a single-blind design. However, at different times, assessment 
was carried out by the same investigator, who was unaware of which drug was being 
administered to patients. 
Withdrawal symptomatology was assessed by the Clinical Institute Withdrawal 
Assessment for Alcohol (CIWA-Ar)
26
, whereas the intensity of alcohol craving was 
evaluated using a 10-cm Visual Analogue Scale (VAS)
27
 and the Italian version of the 
Obsessive and Compulsive Drinking Scale (OCDS)
28
. Psychiatric symptomatology was 
evaluated with the Symptom Check List 90 Revised (SCL-90-R)
29
. Effectiveness measures 





Abstinence from alcohol was determined based on self-evaluation measures and a 
family member interview. Abstinence was confirmed by performing blood alcohol tests at 
each outpatient follow-up visit (patients were tested twice a week after the group therapy 
session), by measuring alcohol abuse hepatic indices (aspartate aminotranferase (AST), 
alanine aminotranferase (ALT), gamma glutamyl-tranpeptidase (GGT)), and mean cellular 
volume (MCV) at the end of the study. Toxicological urinalysis was performed at each 
outpatient control in order to identify polysubstance abuse. Subjects were strongly advised 
against using drugs that could potentially influence craving for alcohol
31,32
. Blood alcohol 
tests and urinalysis were performed twelve times (twice per week, for six weeks) for those 
patients concluding the study procedures. 
Primary study endpoints were maintenance of abstinence and relapse prevention. 
Drinking any alcohol marked the end of abstinence. Relapse was defined as drinking either 
five (four for women) or more standard drinks on a single occasion, or drinking on five or 




. Secondary study endpoints included: number of abstinent days, average daily 
alcohol consumption, retention in treatment, and reduction of alcohol craving. A drink is 
defined as 12 grams of absolute alcohol, roughly corresponding to half a pint of beer, a 
glass of wine, or a single (25ml) measure of spirit. 
Safety parameters were monitored through ECG, urinalysis, haematological and 
clinical chemical analyses of blood samples at the start and at the end of the study. 
Each patient was informed that relapse, non-compliance, or the onset of any severe 
side effects would lead to exclusion from the trial. However, patients were free to leave the 






Primary and secondary efficacy analyses were performed on the intent-to-treat 
population, which included all randomly assigned patients who took at least one dose of 
study medication. 
Student’s t- and Chi-square tests were employed in order to compare socio-
demographic and clinical data with OCDS, VAS, SCL-90-R, QoL and CIWA-Ar scores to 
verify the presence of significant changes during the time period considered (T0-T1). 
Between-groups comparison (TOP vs. PLA) was performed using Student’s t test to 
compare the mean difference between baseline and T1 scores. 
Logistic regression analysis was employed to verify which variable most influenced 
outcome in terms of number of patients remaining abstinent at the end of the study. 
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Alcohol abuse indices were compared between groups and in different moments by 
means of the Chi-square test (abstinent and relapsed patients) and the Student’s t-test (days 




Patients and disposition 
 
 
A total of 80 patients were initially screened; 18 were then excluded from the study, 
leaving 62 patients (38 males and 24 females). Reasons for exclusion were represented by: 
not fulfilment of the diagnosis of Alcohol Dependence according to DSM-IV-TR (8); 
regular use of anticonvulsants (2), antidepressants (4), antipsychotics (3), or previous 
treatment with topiramate (1). No significant differences were observed as to baseline 
characteristics between patients excluded from the study and those who were included in 
the study. Ten patients were excluded during the detoxification phase (9 for drop-out; 1 for 
the onset of suicidal thoughts and psychotic symptoms) and the final study sample 
consisted of 52 patients (32 males and 16 females). Of these, 26 were treated with 
topiramate and 26 with placebo (see Figure 1). 
No statistically significant differences were found between patients assigned to 
topiramate and patients treated with placebo with respect to age, gender, education, marital 
status, employment, craving scores (OCDS; VAS), withdrawal scores (CIWA-Ar), baseline 
psychiatric symptomatology (SCL-90-R, GSI-Index), use of other substances, DSM IV-TR 
Axis I and II comorbidity. The characteristics of the sample are reported in Table 1. 
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Patients with polysubstance abuse and dual diagnosis were equally distributed in the 
two samples. Additional axis I diagnoses included: mood disorders (TOP=4; PLA=7), 
anxiety disorders (TOP=5; PLA=7), impulse control disorders (TOP=1), and eating 
disorders (PLA=1). Additional axis II diagnosis were Borderline (TOP=3; PLA=2), 
Antisocial (TOP=1; PLA=1), Avoidant (TOP=2; PLA=3), Histrionic (TOP=2; PLA=1), 
Passive-aggressive (TOP=1; PLA=1) and Schizoid (TOP=1) personality disorders. 
Substance abuse, other than alcohol, comprised: cannabis (TOP=3; PLA=4), 
cocaine (TOP=2; PLA=3) or benzodiazepine abuse (TOP=3; PLA=4). 






With respect to primary study endpoints (patients abstained and relapsed at T1), 
patients treated with topiramate were more likely to be abstinent (p=0.001; X²= 99.12;) 
than controls. The number of relapsed patients, as confirmed by blood alcohol 
concentrations, was higher in the PLA group than in the TOP group (13 vs 5; X²= 98.82; 
p<0.001). With respect to secondary endpoints, compared to the placebo group, at the end 
of treatment (T1) patients in the TOP group had: a) fewer days of drinking (9.5±8.3 vs 
21.9±13.3; t=2.77; p<0.05); b) lower daily alcohol consumption (2.9±4.3 vs 5.8±4.1; 
t=2.31; p<0.05); c) more days of treatment (43.3±18.5 vs 29.4±12.2; t=2.70; p<0.05); and 
d) were more likely to be retained in treatment at T1 (t=3.89; p<0.01). 
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With respect to craving scores, the TOP group showed a significant reduction after 
6 weeks of treatment (T1) on the VAS for craving (t=2.88; p< 0.5), on the OCDS (t=4.91; 
p< 0.001), and its subscores of OCDS obsessive (t=4.86; p< 0.001) and OCDS compulsive 
(t=4.94; p< 0.001). Likewise the PLA group showed a significant mean reduction in the 
VAS (t=2.21; p< 0.5), OCDS (t=2.13; p< 0.05) and its subscores of OCDS obsessive 
(t=2.09; p< 0.05) and OCDS compulsive (t=2.17; p< 0.05). Mean change from baseline in 
the two groups is described in Figure 2. A significant difference between groups was 
observed for OCDS scores (t=3.01; p<0.01), but not for VAS. Abstinent patients in both 
study groups showed significantly lower OCDS scores than relapsed patients, even after the 
exclusion of alcohol consumption items (t=4.84; p<0.01). 
Withdrawal total scores as measured by the CIWA-Ar were significantly reduced in 
the TOP group (t=4.89; p<0.001) and in the PLA group (t=2.12; p<0.05). A significant 
difference between groups (t=2.66; p<0.05) was found in favour of the TOP group. 
The SCL-90-R general index of “Positive Symptom Total” was significantly 
reduced after 6 weeks of treatment in both groups (TOP: Positive Symptom Total: t=3.12; 
p<0.01; PLA: Positive Symptom Total: t=2.24; p<0.05), whereas the subscales for 
“obsessive-compulsive” (Figure 2), “hostility”, “anxiety” and “depression” showed 
significant reductions only in the TOP group (t=2.86; p<0.01; t=2.88; p<0.05; t=2.21; 
p<0.05; t=2.29; p<0.05). Scores (OCDS, VAS, SCL-90 GSI, CIWA-Ar) at baseline and at 
the end of treatment are reported in Table 2. 
Patients in both groups showed a statistically significant improvement in scores on 
the Quality of Life scale (TOP: t=2.09; p<0.05; PLA: t=2.19; p<0.05), with no difference 
between groups. 
 12 
The number of patients with dual diagnosis reporting a condition of total abstinence 
from alcohol at the end of the study was significantly higher (X²= 98.12; p< 0.01) in the 
TOP group (6/10; 60%) compared to the PLA group (2/8; 25%). 
Logistic regression analysis showed that the reduction of the OCDS scores was the 
most relevant factor (p<0.01) determining the maintenance of the alcohol-free condition in 
all randomised subjects. There was no indication of a separate factor specific to either the 
TOP or PLA group. 
 
Safety and tolerability 
 
Common adverse events (whether or not treatment-related) occurred in 7 patients of 
the TOP group and in 5 patients of the control group, with no statistically significant 
differences between TOP and controls. The overall rate of study discontinuation due to the 
occurrence of adverse events was 3.8 % (n=1) in the TOP group, and 3.8% (n=1) in the 
control group. Somnolence (n=3), dizziness (n=2), psychomotor retardation (n=1) were the 
adverse effects across the TOP group, with 1 case of dizziness being the event that led to 
patient withdrawal from the study. Somnolence (n=2), dizziness (n=1), nausea (n=1), and 
insomnia (n=1) were the adverse events across the control group, with nausea being the 
event that led to patient withdrawal from the study. 
No clinically relevant difference between groups was observed in the mean change 
from baseline for any vital signs, ECGs, haematology, or clinical chemistry parameters. 
Comparing hepatic alcohol abuse indices before and after treatment, we found a significant 
decrease in GGT (p<0.01), AST (p<0.01) and ALT values (p<0.01) in all treatment groups, 
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with no significant difference between groups. This comparison between the reductions 
(Delta) in GGT, AST, and ALT showed a trend in favour of the group of patients treated 
with topiramate (GGT: TOP Δ=-39; PLA: Δ=-28; p=0.062); (AST: TOP Δ=-29; PLA: Δ=-
22; p=0.081); (ALT: TOP Δ=-25; PLA: Δ=-21; p=0.079). Besides, a significant decrease in 
cholesterol levels (TOP: t=3.89; p<0.05; PLA: t=3.89; p<0.05) was reported in both groups 
with no difference between groups. Moreover, for biochemical analysis of glucose, low-
density lipoprotein, high-density lipoprotein, non-esterified fatty acids, and triglycerides, 
there were no significant differences between baseline and end of treatment. Mean change 
in weight from baseline to the end of treatment was –0.9 kg in the TOP group, +0.3 in the 
PLA group. 
Upon drug discontinuation, we observed no side effects. 
The use of other drugs was not reported, apart from two cases of benzodiazepines 
intake at low doses (1 mg lorazepam; 0.5 mg alprazolam). These drugs were taken by the 
subjects without any medical advice, each one in just one occasion. Given the low amount 





Following alcohol detoxification, initiation of treatment aimed at relapse prevention 
is crucial. However, currently approved medications offer limited benefits, while other 
treatments are still under investigation, and they may cause problems in terms of 
tolerability and side effects
2
. In this multicentre, randomised, single-blind placebo-
 14 
controlled clinical trial, we intended to investigate the safety and efficacy of low dose (100 
mg/day) topiramate in detoxified alcohol dependent subjects, given positive results from 
previous studies with higher doses, in which the burden of side effects was, however, 
significant
35,36
. However, in one of these studies, the burden of side effects was 
significant
36
. To our knowledge, this is the first placebo-controlled trial to evaluate the 
efficacy of low-dosage topiramate for alcohol dependence. Additionally, though data were 
collected in an outpatient setting, our sample was composed of heavy drinkers, with an 
average intake of 6 drinks per day and a history of abuse/dependence for over 3 years. 
The main finding of this study is that low-dose topiramate, associated with 
rehabilitation, improved abstinence in the first 6 weeks after detoxification, reduced craving 
levels and symptoms in the areas of anxiety, depression, hostility and obsessive-
compulsivity, compared to subjects receiving placebo and rehabilitation therapy. 
Our results are consistent with previous placebo-controlled studies on higher doses 
of topiramate (both with a maximum dosage of 300 mg/day)
35,36
 and with confrontation 
trials in which topiramate showed a good outcome compared to naltrexone
37,38
. However, in 
these previous studies, the optimal dose was not established. In a double-blind, randomized, 
placebo-controlled, 14-week clinical trial
36
, six doses were adopted in the dose-escalating 
scheme (in mg/day): 25, 50, 100, 150, 200, and 300, with the dose of 150-300 mg/day 
recognized as the therapeutic dose that need to be administered to obtain a good risk-benefit 
profile. A major concern was related to topiramate’s adverse effects. Johnson et al. 
36
 found 
that the attrition rates due to adverse events were 18.6% (34 of 183) in subjects who 
received topiramate. The most common adverse events were paraesthesia, anorexia, 
memory impairment or lack of concentration, and taste perversion. These symptoms appear 
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to be dose related, are prominent especially during the titration period, and usually decrease 
within a few days
39
. Thus, most patients, who discontinue topiramate due to its side effects, 
do so early in treatment, reducing potential benefits. A key objective of the present study 
was to establish the efficacy and side effect profile of low-dose topiramate (up to 100 
mg/day), in order to improve adherence to treatment. In our sample, a low proportion of the 
topiramate group experienced adverse effects, but no significant difference was recorded 
compared to the control group. Moreover, these adverse effects were tolerable and did not 
cause dropouts. 
Our data are consistent with a previous open-design study in which topiramate up to 




A novel finding of the present study is the influence of topiramate on hostility and 
obsessive-compulsivity. This is consistent with other studies in which topiramate was 







, and obsessive-compulsive disorder
43
. Improvement in 
hostility and obsessive-compulsivity may contribute to the reduction of craving, relapses 
and withdrawal symptoms. Treatment of alcohol withdrawal and protracted withdrawal 
syndromes
44
 is another possible mechanism involved in topiramate efficacy, given the 
mean improvement of withdrawal symptoms in the topiramate-treated subjects, which was 
significantly superior to that of the control group. This should be considered in relapse 
prevention strategies. 
Finally, liver function tests in the treated subjects showed significantly improved 
results. This is obviously due to the suspension of alcohol intake, as indicated by the 
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decrease in GGT, but the parallel reduction in indices of hepatocellular damage point to the 
safety of this drug. Haematological and ECG data corroborate what has been previously 
described with topiramate in other psychopathological and neurological conditions
45
, 
confirming its favourable safety profile in alcoholics. 
The main limitations of our study are: 1) the small sample size; 2) the short follow-
up period with lack of important information on the long-term efficacy of topiramate; 3) the 
single-blind design. However, it is worth highlighting that the first weeks of abstinence are 
crucial in the management of alcohol dependent patients, considering that craving is high, 
the presence of post-detoxification anhedonia is considerable
46,47




The results of this study need to be interpreted with caution due to these limitations. 
Though we did not test for efficacy in different subpopulations of alcoholics, we believe 
that specific subpopulations of alcohol abusers, such as Cloninger type II alcoholics
49
 and 
subjects with specific typologies of craving
50
, could benefit from topiramate in terms of 
efficacy, given the specific pharmacodynamics properties of this drug. However, this data 
was not investigated by our study, and may only represent a hypothesis that need to be 
confirmed in future trials. 
Establishing the optimal dose of topiramate has important clinical implications. It 
will considerably extend the population of patients receiving topiramate, it will enable 
those on this drug to benefit from a more tolerable adverse event profile, and it will 
improve compliance
51
. This approach could improve the response to topiramate in subject 
suffering from alcohol dependence, in parallel with the possibility to identify new 
pharmacogenomics variables, as recently reported by Kranzler et al.
52
 for the rs2832407 C-
 17 
allele homozygotes. Future studies with larger samples, up to those tested at higher 
dosages, and possible comparison vs. both placebo and other dosages are mandatory. 
Determining the smallest dose of topiramate resulting in efficacy, thereby achieving 
the optimum balance between therapeutic benefits and adverse event profile, was a notable 
challenge in the use of topiramate to treat alcohol dependence. The findings from our 
placebo-controlled study, despite the above-mentioned limitations, support the potential 
usefulness of topiramate, even at a dose of 100 mg/day. Topiramate could, therefore, be 
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Table 1. Socio-demographic and clinical data of subjects. Data are 
expressed as absolute numbers with percentage given in brackets or 
as mean  standard deviation.  
 










46.6  11.5  45.5  11 
Marital status   
Single 7 (27) 9 (35) 
Married 12 (46) 9 (35) 
Separated/Divorced 
 
7 (27) 8 (30) 
Level of education   
Elementary School 1 (4) 1 (4) 
Lower Secondary School 7 (26) 6 (23) 
High School Education 14 (55) 16 (62) 
Degree 
 
4 (15) 3 (11) 
Unemployment 
 




15.5  5.2 
10 
 
17.2  9.4 
Multiple substance abuse  
 
Dual Diagnosis  (Axis I) 
 
















6.74  3.6 
 
15.5  9.2 
 
3.4  3.8 
 







5.75  4.3 
 
12.7  6.2 
 
3.9  3.6 
 





Table 2. Scores (mean ± Standard Deviation (SD)) at the Visual Analogue Scale for 
Craving (VAS), Obsessive Compulsive Drinking Scale (OCDS), Symptom Checklist-
90-Revised (SCL-90-R), General Symptoms Index (GSI), Clinical Institute 
Withdrawal Assessment for Alcohol-revised (CIWA-Ar) of Topiramate and Control 
groups at baseline (T0), and at the end of the study (T1). Level of significance are 






Mean      SD 
T 1 
Mean      SD 
    P 
    
VAS    
Topiramate 3,4        1,6 0,3        0,1 p< 0.05 
Control 3,9        1,7 1,0        0,9 p< 0.05 
    
OCDS - Total    
Topiramate 15,5        9.2 0,5       0.6 p<0.001 
Control 12,7        6.2 5,0       4.6 p< 0.05 
    
SCL-90-R (GSI)    
Topiramate 0,91       0.6 0,36      0.3 p< 0.01 
Control 0,92       0.5 0,58      0.3 p< 0.05 
    
CIWA-Ar    
Topiramate 6,7       3.6 0,5       0.7 p< 0.001 
Control 
 
5,7       4.3 1,1       2.0 p< 0.05 
 









(N=80)   
Patients included  
  
(N=62)   






















Alcohol  Detox 
Figures
Fig 2: Obsessive Compulsive Drinking Scale 
(OCDS), Visual Analogue Scale for Craving (VAS), 
and Obsessive-compulsive subscale of the Symptom 
Check List (SCL-90-R) mean change from baseline at 
the last assessment (T1) 










































































These (in bold) are the answers to the points proposed by the reviewer. As 
supplemental data file I have also attached a further revised version with the 
revised points in yellow. 
 
 
Reviewer #1:  
 
The issue of using low doses of topiramate is critical, hence studies like this one 
are welcome and interesting. Results are relevant and the manuscript is well-
written. I only have a few minor comments: 
 
The sentence "To our knowledge, this is the first placebo-controlled trial to evaluate 
the efficacy of topiramate for alcohol dependence." should be revised to specify that 
it refers to low doses, i.e., 100mg/d. 
 
As suggested the sentence has been revised. 
 
Introduction and Discussion should be revised taking into account a recent RCT 
with topiramate 200mg/d (Kranzler et al. Am J Psychiatry 2014). In particular, the 
Discussion should emphasize the importance of future studies testing the 
pharmacogenetics of topiramate 100mg/d. 
 
The recent RCT and the importance of future studies has been emphasized. 
 
 
Reviewer #2:  
 
The utility of topiramate for the treatment of alcohol and other drug use disorders is 
limited by significant dose-dependent side effects and clinical trials showing the 
efficacy of low dose topiramate are potentially of great interest. This paper reports 
on a randomized single blind investigation of the efficacy of topiramate up to 100 
mg bid in reducing alcohol use and craving following detoxification. The background 
is detailed, statistical analysis is appropriate, and methods and results are clearly 
explained.  
 
Below are observations/suggestions: 
 
1) 'Abstinence was confirmed by performing blood alcohol tests at each outpatient 
follow-up visit' (methods p 8) It would be helpful to report the number of visits and 
blood/toxicology drug tests. 
 
As suggested we reported in the text the number of visits and tests 
 
 
2) 'Subjects were strongly advised against using drugs that could potentially 
Cover Letter
influence craving for alcohol' (methods p 8). Please report any other drug use in the 
results. 
 
In the results we have now reported the use of other drugs. 
 
3) Results: Please report n,% and/or t values for all comparisons. 
 
As suggested we reported T values for all comparisons and specified 
numbers where more significant 
 
4) Results: Were blood alcohol tests confirming self-reported use? 
 
Yes, blood alcohol tests confirmed the use reported by the patients. We have 
now declared in the study that bac confirmed what was reported by the 
patients. 
 
5) '18 were then excluded (as they did not fulfil inclusion criteria)..' (results p 10) 
were there any common exclusion factors? They could be summarized in the 
consort graph. 
 
We reported the reasons for exclusion in the results section. 
 
6) 'Ten patients were excluded during the detoxification phase' (results p 10) please 
report the reason for exclusion.  
 
We have now reported the reasons for exclusion in the results section. 
 
 
7) '6 of treatment' (results p11) should read '6 weeks of treatment'. 
 
The correction has been addressed. 
 
8) The one described in the manuscript is a small to medium treatment effect. In the 
opinion of the Authors future studies should be comparing low dose topiramate with 
placebo or with higher dose topiramate? And what should the appropriate sample 
size be? 
 
We think that other studies with low-dosage of topiramate should be 
replicated with a sample size of 100 to 250 subjects, as for the placebo-
controlled study with higher dosages of topiramate. A comparison trial could 




Reviewer #3:  
 
This manuscript describes a single-blind, placebo-controlled trial of topiramate 100 
mg/day in 52 alcohol-dependent patients. The findings show that low-dose 
topiramate can be efficacious in reducing drinking measures in alcoholics, which is 
an important contribution to the literature.  
 
The major concern I have is over the analytic approach. In a number of cases (e.g., 
GGT, AST, ALT concentrations), the analysis compares pre- and post-treatment 
values, rather than comparing topiramate and placebo groups, which can be 
misleading. A preferable analytic approach would be to use a two-factor analysis in 
which both time (pre/post) and medication group (topiramate/placebo) are analyzed 
as main effects and the interaction of these factors is also examined.  
 
We agree with the reviewer We have performed a comparison between 
topiramate and placebo, comparing the differences (delta) between baseline 
and the end of the treatment for both the treatment. A significant difference 
was not evidence, but only a trend. We reported this data in the results. 
Probably, the low sample size, the relatively good percentage of responders 
in the placebo group, and the short timeframe of the study are factors that 
can explain this data. 
 
In addition, there are a number of omissions or errors that should be addressed. 
 
1. There is no mention of the approval of nalmefene (Selincro) in the EU (p. 2). 
 
We have now reported this data, that was not available when the first draft of 
this paper was prepared. 
 
2. There is an older study (http://www.ncbi.nlm.nih.gov/pubmed/18215213) and 





As suggested these studies have been reported. 
 
3. Although patients were recruited from both inpatient and outpatient sources, I 
could not find the proportion of patients from each of those sources and whether 
there were differences in the proportion of each in the two treatment groups. The 
inclusion of this measure in Table 1 would be helpful to the reader. 
 
All the patients recruited were in an outpatients setting. The Day-Hospital of 
Psychiatry and Drug Dependence may be defined as an outpatients unit, 
where the subjects remain the time required for the pharmacological and/or 
psychosocial therapy. The Day-Hospital is opened only in the morning, and it 
does not allow clients to stay during the night as in a inpatient unit. We have 
now specified this aspect in the methods. 
 
4. The logistic regression analysis of abstinence, in which the OCDS was a 
significant predictor, doesn't take into account the fact that the drinking measures in 
the OCDS may have been confounded with the outcome measure. 
 
Also excluding the items correlated with the use of alcohol the differences 
remained significant. We data had been already reported in the result section: 
“Abstinent patients in both study groups showed significantly lower OCDS 
scores than relapsed patients, even after the exclusion of alcohol 
consumption items (P<0.01)” 
 
5. Although statistical significance is reported for a variety of analyses throughout 
the manuscript, the statistics themselves (e.g., chi-square values, regression beta 
statistics) are omitted, with only p-values being provided. In some cases, 
statements are made concerning significant differences and the actual values (e.g., 
GGT, AST, ALT concentrations) are not provided. Similarly, the overall study 
completion rates in the two medication groups are not provided. 
 
As suggested we have now reported these important details. 
 
6. There is no information concerning the single-blind study design. Presumably, 
the investigators knew which patients received active or placebo medication. If 
that's true, it should be made clear whether those individuals interacted with the 
patients, which could confound the results. If available, it would also be useful to 
know which treatment the patients believed they received. In any case, this should 
be included as a limitation on p. 15. 
 
In agreement with the reviewer we have now included this as a limitation. 
However, we report that the psychometric evaluations have been made by 
blind raters and the investigators did not influenced the evaluation. 
 
7. On p. 13, there are statements made regarding prior topiramate studies 
(references 32 and 33) that are incorrect. Although in the multi-center topiramate 
study (ref. 33) there was greater dropout due to topiramate adverse events, this 
was not true in the single-site study (ref. 32), where the active medication was very 
well tolerated. Similarly, the same two citations are used in relation to dosing of 
150-300 mg/day. This is incorrect because both studies used a maximal dosage of 
300 mg/day. 
 
As suggested, this issue has been addressed in the discussion section. 
 
8. The statement on p. 13 is incorrect: "To our knowledge, this is the first placebo-
controlled trial to evaluate the efficacy of topiramate for alcohol dependence." 
 
In agreement with the reviewer we have now corrected the statement. 
 
9. There are typographical, spelling, or grammatical errors throughout the 
manuscript (e.g., "die" instead of "day" when describing daily dosages). 
 
We have now adequately revised the paper. 
 
10. In the penultimate paragraph on p. 15, what the authors believe should not be 
included, except as a hypothesis, as there is nothing in the current study that 
addresses whether subpopulations of alcoholics would specifically benefit from 
topiramate treatment. 
 
In this study the analysis of subpopulations receiving topiramate has not 
been made. However, to do and propose hypothesis could be of some 
interest, indicating possible new therapautical strategies. However, we have 
modified and clarified the sentence. 
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